This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
by Zacks Equity Research
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.
RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug
by Zacks Equity Research
RedHill's (RDHL) RHB-204 gets Orphan Drug designation from the European Commission for the treatment of nontuberculous mycobacteria (NTM) disease
Redhill Biopharma Ltd. (RDHL) Could Find Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Redhill Biopharma Ltd. (RDHL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
RedHill (RDHL) COVID Pneumonia Drug Meets Study Goal, Stock Up
by Zacks Equity Research
Redhill's (RDHL) opaganib achieves a significant reduction in mortality in hospitalized patients with severe COVID-19 pneumonia based on new data from the phase II/III study.
RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study
by Zacks Equity Research
RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal.
RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis
by Zacks Equity Research
Opaganib, Redhill's (RDHL) candidate for COVID-19, achieves a significant reduction in kidney fibrosis in preclinical studies.
Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Incyte (INCY), among others, have been in focus in the biotech industry over the past week.
Strength Seen in Redhill Biopharma Ltd. (RDHL): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
Redhill Biopharma Ltd. (RDHL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
RedHill (RDHL) Doses First Patient in Phase II/III COVID-19 Study
by Zacks Equity Research
RedHill (RDHL) doses first patient in phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care.
RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation
by Zacks Equity Research
RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.
RedHill (RDHL) COVID-19 Drug Shows Promise in Mid-Stage Study
by Zacks Equity Research
RedHill's (RDHL) opaganib achieves greater improvement in reducing oxygen requirement compared to placebo in a phase II study evaluating it in patients hospitalized with COVID-19 pneumonia.
Is the Options Market Predicting a Spike in RedHill Biopharma (RDHL) Stock?
by Zacks Equity Research
Investors need to pay close attention to RedHill Biopharma (RDHL) stock based on the movements in the options market lately.
RedHill (RDHL) Expands Opaganib Manufacturing Capacity in US
by Zacks Equity Research
RedHill (RDHL) expands its manufacturing capacity to support the potential emergency use applications to be filed for opaganib to address severe COVID-19 pneumonia in the United States.
RedHill (RDHL) to Begin Study on Second Coronavirus Candidate
by Zacks Equity Research
The FDA clears RedHill's (RDHL) IND filing for a phase II/III study on its second coronavirus candidate RHB-107 to treat patients with symptomatic COVID-19 who do not require hospitalization.
RedHill (RDHL) Closes Enrollment for Phase II Coronavirus Study
by Zacks Equity Research
Redhill (RDHL) completes enrollment in the phase II study on opaganib in patients hospitalized with severe COVID-19 pneumonia.
RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation
by Zacks Equity Research
RedHill (RDHL) gets Orphan Drug status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.
RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib
by Zacks Equity Research
The Brazilian Health Regulatory Agency okays RedHill's (RDHL) to conduct a phase II/III study on opaganib for treating patients with severe COVID-19 infection and pneumonia. Stock up.
RedHill (RDHL) to Study Opaganib for Severe Coronavirus in UK
by Zacks Equity Research
RedHill's (RDHL) CTA gets approval in the United Kingdom to start a phase II/III study on opaganib for patients hospitalized with severe COVID-19 infection and pneumonia.
RedHill Files CTA for Coronavirus Study on Opaganib in Russia
by Zacks Equity Research
RedHill (RDHL) submits a Clinical Trial Application in Russia for a phase II/III study on opaganib to treat patients detected with severe COVID-19 infection and pneumonia. Stock up.
Is Redhill Biopharma (RDHL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (RDHL) Outperforming Other Medical Stocks This Year?
Is Redhill Biopharma (RDHL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (RDHL) Outperforming Other Medical Stocks This Year?
RedHill's Oncology Candidate to be Tested for Coronavirus
by Zacks Equity Research
RedHill (RDHL) inks a deal with NIAID for non-clinical testing of its investigational candidate RHB-107 to evaluate its activity against COVID-19. Stock up.
RedHill (RDHL) Soars: Stock Adds 9.2% in Session
by Zacks Equity Research
RedHill (RDHL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for April 9th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 9th
Top Ranked Momentum Stocks to Buy for April 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 7th